Gland Pharma beat muted expectations for Q2FY25. There was increased Ebitda (Earnings before interest, taxes, depreciation and amortisation) loss at Cenexi, the CRAM subsidiary. However, overall Ebitda margin was better than expectations at 21.1 per cent. But given two years of earnings decline in FY23 and FY24, the business may have bottomed and upper-teens EPS (earnings per share) growth looks possible over next two financial years.
Analysts are downgrading optimistic EPS estimates for FY25 and FY26, due to continuing slowdown in US sales and a temporary issue at Cenexi's site in Belgium. Uptick in the biologics business was also slow. But H2FY25 onwards, there's hope for better volumes for base products like Enoxaparin, Ebitda break-even for Cenexi, and better business in biologics.
Esta historia es de la edición November 06, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición November 06, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Technology changes BFSI sector
Firms in the industry are undergoing a major digital transformation, with technologies - Cloud, Al, GenAI, RPA, and blockchain - leading the way, says a Business Standard-Everest Group report
Making sense of India's real estate boom
Growth drivers in real estate include urbanisation, disposable incomes, and demand for residential, commercial, and logistics spaces, according to a Business Standard-Knight Frank report
THE BIGGEST BFSI SUMMIT IS EVEN BIGGER NOW
The largest financial sector event in the country - the Business Standard BFSI Insight Summit - is back this year in a bigger form.
Shares of Adani Ports anchor at 5-month low
Down 5% in two days after business update for October
Markets rebound as investors cast wide net for value
In-demand financial stocks drive the rally
Global mkt: Stocks, Treasury yields gain as US votes
World stocks rose and Treasury yields rebounded on Tuesday while an index of market volatility retreated, as markets awaited early indications of the outcome of a knife-edge US election, with only currency markets showing some jitters.
Upper-teens EPS growth likely for Gland Pharma in next two financial yrs
Gland Pharma's Q2FY25 results beat muted expectations, with upper-teens EPS growth projected over the next two financial years despite a slowdown in US sales and temporary issues at its Cenexi subsidiary.
Sagility India IPO booked 22% on Day 1
The initial public offering (IPO) of Sagility India Ltd, a technology-enabled services provider in the health care space, received 22 per cent subscription on the first day of bidding on Tuesday.
Record FPI exodus throws a shadow on stock markets
Foreign investors are souring on India's stock market, selling a record amount of shares amid signs the South Asian nation's post-pandemic economic boom is losing steam.
Govt may divest 2.5% in HZL through OFS
The Centre is planning to sell 2.5 per cent of the total share capital of Hindustan Zinc Ltd (HZL) through an offer for sale (OFS) on Wednesday and Thursday for ₹505 per share.
